Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 522-529

  Lehman, Dara A ^a,b   Chung, Michael H ^b   Mabuka, Jennifer M ^a,b   John Stewart, Grace C ^b   Kiarie, James ^c   Kinuthia, John ^c   Overbaugh, Julie ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Antiretroviral resistance; HAART; HIV; Mother to child transmission; Prophylaxis

Indexed keywords

LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASE SEQUENCE; DNA PRIMERS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; MUTATION, MISSENSE; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; ZIDOVUDINE;

EID: 68449090647     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181aa8a22     Document Type: Article

References (36)

1. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infant: towards universal access. Available at: http://www.who.int/hiv/pub/guidelines/pmtctguidelines3.pdf. Accessed July 17, 2006.
2. Gray GE, Saloojee H. Breast-feeding, antiretroviral prophylaxis, and HIV N Engl J Med. 2008;359:189-191.
3. Mofenson LM. Antiretroviral prophylaxis to reduce breast milk transmission of HIV type 1: new data but still questions. J Acquir Immune Defic Syndr. 2008;48:237-240.
4. Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. February 4, 2008;359:119-129.
5. Thomas T, Masaba R, Ndivo R, et al. Prevention of mother-to-child transmission of HIV-1 among breastfeeding mothers using HAART: the Kisumu Breastfeeding Study, Kisumu, Kenya, 2003-2007. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 4, 2008; Boston, MA.
6. Kilewo C, Karlsson K, Ngarina M, et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding mothers prophylactically with triple antiretroviral therapy in Dar es Salaam, Tanzania - The MITRA plus study. Presented at: 4th International AIDS Society Conference on HIV Pathogenesis and Treatment; July 22-25, 2007; Sydney, Australia.
7. Kourtis AP, Jamieson DJ, de Vincenzi I, et al. Prevention of human immunodeficiency virus-1 transmission to the infant through breastfeeding: new developments. Am J Obstet Gynecol. 2007;197:S113-S122.
8. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS. 2007;21:965-971.
9. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008;47:421-424.
10. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus (HIV-1) transmission. Rev Med Virol. 2007;17:381-403.
11. Arrive E, Newell ML, Ekouevi DK, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36:1009-1021.
12. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N EnglJ Med. 2004;351:229-240.
13. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N EnglJ Med. 2007;356:135-147.
14. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 2008;5:e158.
15. Richman D, Shih CK, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse trans-criptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991;88:11241-11245.
16. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
17. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283-288.
18. Perez H, Vignoles M, Laufer N, et al. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther. 2008;13:135-139.
19. Chung MH, Kiarie JN, Richardson BA, et al. Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 RNA: a phase II randomized clinical trial. Antivir Ther. 2008;13:799-807.
20. Lehman DA, Chung MH, John-Stewart GC, et al. HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission. AIDS. 2008;22:1475-1485.
21. DeVange Panteleeff D, Emery S, Richardson BA, et al. Validation of performance of the Gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples. J Clin Microbial. 2002;40:3929-3937.
22. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbial. 2000;38:2688-2695.
23. ANRS AC11 Resistance Study Group. PCR and sequencing procedures: HIV-1, version February 2008. Available at: http://www.hivfrenchresis-tance.org/ANRS- procedures.pdf. Accessed May 15, 2008.
24. PAUP: phylogenetic analysis using parsimony [computer program]. Champaign, IL: Natural History Survey; 1991.
25. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30-36.
26. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
27. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20:995-1002.
28. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094-7099.
29. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;195:711-715.
30. Kassaye S, Lee E, Kantor R, et al. Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses. 2007;23:1055-1061.
31. Dao H, Mofenson LM, Ekpini R, et al. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. Am J Obstet Gynecol. 2007;197:S42-S55.
32. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'lvoire. J Infect Dis. 2006;193:482-487.
33. McIntyre J, Martinson N, Gray G, et al. Addition of short course combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. Paper presented at: The 3rd IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio de Janeiro, Brazil.
34. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005;40:24-29.
35. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24-29.
36. Tonwe-Gold B, Ekouevi DK, Viho I, et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med. 2007;4:e257.